Isoquinoline compounds and their use in treating AhR imbalance
The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
1. A compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof.
2. The compound of claim 1 that is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according claim 1 and a pharmaceutically acceptable carrier or diluent.
4. The pharmaceutical composition of claim 3 , wherein the pharmaceutically acceptable carrier or diluent is suitable for topical administration.
5. The pharmaceutical composition of claim 3 wherein the carrier or diluent is suitable for a gel topical administration.
6. The pharmaceutical composition of claim 3 wherein the carrier or diluent is suitable for a cream topical administration.
7. A compound of claim 1 that is at least 90% pure by weight.
8. A compound of claim 1 that is at least 95% pure by weight.
9. A compound of claim 1 that is at least 98% pure by weight.
10. A compound of claim 1 that is s at least 99% pure by weight.